There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adaptimmune Therapeutics (ADAP) and Heron Therapeutics (HRTX) with bullish sentiments.
Adaptimmune Therapeutics (ADAP)
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Adaptimmune Therapeutics, with a price target of $15.00. The company’s shares closed last Thursday at $5.36.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 41.8% and a 54.2% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Monopar Therapeutics Inc, and Actinium Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Adaptimmune Therapeutics with a $10.00 average price target.
See today’s analyst top recommended stocks >>
Heron Therapeutics (HRTX)
Needham analyst Serge Belanger maintained a Buy rating on Heron Therapeutics today and set a price target of $28.00. The company’s shares closed last Thursday at $17.35.
According to TipRanks.com, Belanger is a 3-star analyst with an average return of 1.2% and a 38.7% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and KalVista Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Heron Therapeutics with a $27.20 average price target, implying a 57.0% upside from current levels. In a report released today, Northland Securities also maintained a Buy rating on the stock with a $35.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
